Tags

Type your tag names separated by a space and hit enter

Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.
Cytometry B Clin Cytom. 2009 Jul; 76(4):249-60.CB

Abstract

BACKGROUND

Measuring lymphocyte activation provides information in addition to CD4(+) T-cell count for immune monitoring of HIV-1 infected patients. CD38 is a well-established activation marker that is generally analyzed on the whole population of CD8(+) T-cells. Focusing specifically on CD38 high expression (CD8(+)/CD38(bright)) may be an interesting surrogate gating strategy because CD38(bright) characterizes principally activated memory cells.

METHODS

CD8(+)/CD38(bright) was investigated in 1,353 HIV-1 infected patients over a one-year period to establish relevant cutoff values and clarify the relationships of this marker with HIV-1 RNA viral load (VL) and CD4(+) T-cell count.

RESULTS

The CD8(+)/CD38(bright) (>8,500 CD38 binding site per cells) is well correlated with HIV-1 VL (r = 0.87, P < 0.001) in this longitudinal follow-up of nonimmunodepressed patients that initiated antiviral therapy (ART). In aviremic patients on ART, the marker was highly predictive of VL rebound (sensitivity 93%, specificity 64% for a VL level of detection >200 copies/ml). While the CD8(+)/CD38(bright) moderately correlated with CD4(+) T-cell count independently of the VL (r = -0.37, P < 0.001), it increased dramatically in aviremic patient groups that exhibited profound CD4(+) T-cell depletion (median 39% for CD4(+) T-cell counts <50/mm(3)). This result indicates that other additional immunological and/or viral factors than readily detectable HIV-1 replication appears to be involved in T-cell activation of immunodepressed individuals.

CONCLUSIONS

CD8(+)/CD38(bright) is an effective marker for monitoring T-cell activation, which is a central factor of HIV-1 pathogenesis. This gating strategy requires only a single additional staining in conventional four color CD4 protocols.

Authors+Show Affiliations

Laboratoire de Virologie, Centre Hospitalier Universitaire de Montpellier, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19072838

Citation

Tuaillon, Edouard, et al. "Close Association of CD8+/CD38 Bright With HIV-1 Replication and Complex Relationship With CD4+ T-cell Count." Cytometry. Part B, Clinical Cytometry, vol. 76, no. 4, 2009, pp. 249-60.
Tuaillon E, Al Tabaa Y, Baillat V, et al. Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count. Cytometry B Clin Cytom. 2009;76(4):249-60.
Tuaillon, E., Al Tabaa, Y., Baillat, V., Segondy, M., Picot, M. C., Reynes, J., & Vendrell, J. P. (2009). Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count. Cytometry. Part B, Clinical Cytometry, 76(4), 249-60. https://doi.org/10.1002/cyto.b.20467
Tuaillon E, et al. Close Association of CD8+/CD38 Bright With HIV-1 Replication and Complex Relationship With CD4+ T-cell Count. Cytometry B Clin Cytom. 2009;76(4):249-60. PubMed PMID: 19072838.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count. AU - Tuaillon,Edouard, AU - Al Tabaa,Yassine, AU - Baillat,Vincent, AU - Segondy,Michel, AU - Picot,Marie-Christine, AU - Reynes,Jacques, AU - Vendrell,Jean-Pierre, PY - 2008/12/17/entrez PY - 2008/12/17/pubmed PY - 2009/8/26/medline SP - 249 EP - 60 JF - Cytometry. Part B, Clinical cytometry JO - Cytometry B Clin Cytom VL - 76 IS - 4 N2 - BACKGROUND: Measuring lymphocyte activation provides information in addition to CD4(+) T-cell count for immune monitoring of HIV-1 infected patients. CD38 is a well-established activation marker that is generally analyzed on the whole population of CD8(+) T-cells. Focusing specifically on CD38 high expression (CD8(+)/CD38(bright)) may be an interesting surrogate gating strategy because CD38(bright) characterizes principally activated memory cells. METHODS: CD8(+)/CD38(bright) was investigated in 1,353 HIV-1 infected patients over a one-year period to establish relevant cutoff values and clarify the relationships of this marker with HIV-1 RNA viral load (VL) and CD4(+) T-cell count. RESULTS: The CD8(+)/CD38(bright) (>8,500 CD38 binding site per cells) is well correlated with HIV-1 VL (r = 0.87, P < 0.001) in this longitudinal follow-up of nonimmunodepressed patients that initiated antiviral therapy (ART). In aviremic patients on ART, the marker was highly predictive of VL rebound (sensitivity 93%, specificity 64% for a VL level of detection >200 copies/ml). While the CD8(+)/CD38(bright) moderately correlated with CD4(+) T-cell count independently of the VL (r = -0.37, P < 0.001), it increased dramatically in aviremic patient groups that exhibited profound CD4(+) T-cell depletion (median 39% for CD4(+) T-cell counts <50/mm(3)). This result indicates that other additional immunological and/or viral factors than readily detectable HIV-1 replication appears to be involved in T-cell activation of immunodepressed individuals. CONCLUSIONS: CD8(+)/CD38(bright) is an effective marker for monitoring T-cell activation, which is a central factor of HIV-1 pathogenesis. This gating strategy requires only a single additional staining in conventional four color CD4 protocols. SN - 1552-4957 UR - https://www.unboundmedicine.com/medline/citation/19072838/Close_association_of_CD8+/CD38_bright_with_HIV_1_replication_and_complex_relationship_with_CD4+_T_cell_count_ L2 - https://doi.org/10.1002/cyto.b.20467 DB - PRIME DP - Unbound Medicine ER -